Clinical trial
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or…
NCT00486668 · NSABP Foundation Inc, Other · Unknown status
Key facts
| NCT number | NCT00486668 |
|---|---|
| Title | A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer |
| Official title | A Randomized Phase III Trial of Neoadjuvant Therapy for Patients With Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered With Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies… |
| Lead sponsor | NSABP Foundation Inc, Other |
| Collaborators | GlaxoSmithKline Industry |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Invasive Breast Cancer |
| Intervention type | Drug |
| Interventions | doxorubicin, cyclophosphamide, paclitaxel, trastuzumab, lapatinib |
| Enrollment | 529 |
| Start date | Jul 1, 2007 |
| Primary completion | Jun 1, 2012 |
| Completion | Mar 1, 2017 |
| First posted | Jun 15, 2007 |
| Last update posted | Jun 6, 2016 |
| Countries | Canada, Puerto Rico, United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: